- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injections of lanadelumab.
These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.
Initial dose: 300mg every 2 weeks.
Patients who remain attack free with treatment: consider 300mg every 4 weeks.
Additional Dosage Information
If a dose is missed, administer as soon as possible, ensuring there are at least 10 days between doses.
To be administered as a subcutaneous injection into the abdomen, thighs or upper outer arms. It is recommended that the injection site is rotated.
Children under 12 years
Precautions and Warnings
Treatment to be initiated and supervised by a specialist
For subcutaneous use only
Record name and batch number of administered product
Self-admin. - only if adequately trained and have access to expert advice
Vary injection site during prolonged therapy
Advise patient to stop therapy & contact Dr if hypersensitivity signs occur
May affect results of some laboratory tests
Pregnancy and Lactation
Use lanadelumab with caution during pregnancy.
The manufacturer does not recommend using lanadelumab during pregnancy. Animal studies do not indicate direct/indirect harmful effects relating to reproductive or developmental toxicity. At the time of writing there is limited human data available. Risks are unknown.
Use lanadelumab with caution during breastfeeding.
The manufacturer notes that human immunoglobulins are excreted in breast milk during the first few days after birth but this soon decreases to low concentrations. A risk to the breastfed infant during this time cannot be excluded, however after this period lanadelumab can be used if clinically needed.
Alanine aminotransferase increased
Aspartate aminotransferase increased
Local reaction at injection site
Effects on Laboratory Tests
Interference with coagulation test
Lanadelumab can increase activated partial thromboplastin time (aPTT) due to its interaction with the aPTT assay. In patients treated with this medication, no increases in aPTT were associated with abnormal bleeding adverse events.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: May 2021
Summary of Product Characteristics: Takhzyro 300mg solution for injection in vial. Shire Pharmaceuticals Ireland Limited. Revised July 2020.
Summary of Product Characteristics: Takhzyro 300mg solution for injection in pre-filled syringe. Shire Pharmaceuticals Ireland Limited. Revised July 2020.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 20 May 2021
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.